北京康辰药业股份有限公司 关于2023年限制性股票激励计划回购注销实施公告

Core Points - The company has decided to repurchase and cancel a total of 346,000 restricted stocks due to four incentive recipients no longer qualifying for the incentive program after leaving the company [2][4][5] Group 1: Repurchase and Cancellation Details - The repurchase and cancellation of restricted stocks were approved during multiple board meetings held on April 25, June 23, and August 27, 2025 [3][4] - The repurchase involves 140,000 shares from one recipient and 206,000 shares from three other recipients [2][3] - The company has opened a dedicated securities account for the repurchase process and expects the cancellation to be completed by December 8, 2025 [5][6] Group 2: Legal and Compliance Aspects - The company has confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, including the "Management Measures for Equity Incentives of Listed Companies" [7][8] - A legal opinion from Beijing Guofeng Law Firm states that the procedures followed for the repurchase and cancellation are in accordance with applicable regulations [8]